Clinical Trial Update: A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure [Phase 2]

View source ↗

Summary

Phase II dose-ranging, open-label trial evaluating foscarnet salvage therapy for AIDS patients with sight-threatening CMV retinitis who cannot be treated with g…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Retinitis
• HIV Infections

Drugs mentioned

• Foscarnet (foscarnet)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Cytomegalovirus Retinitis, HIV Infections | Phase 2 | Status: COMPLETED